Awarded Grants

 

The ODC offers over 50 grant opportunities in 30+ disease areas annually to researchers across the globe, as well as within the Penn and CHOP communities. Since 2011, the ODC has funded 400 awards totaling $37,611,872 to 120+ institutions in 25 countries worldwide

See below for a complete list of ODC-awarded grants since 2011.

 
 
 

Awarded Grants

Featured
Genetic models to progress treatments for IQSEC2 related pharmacoresistant epilepsy.

Cheryl Shoubridge

University of Adelaide

$30,000

Establishment of a female model of IQSEC2-associated disorders and AAV-mediatedtreatment of the phenotypes.

Takuma Mori

Shinshu University School of Medicine

$15,000

A Novel Approach for the Treatment of IQSEC2-mediated Disease.

Sahar Isa Da’a

Sidra Medicine, Qatar Cardiovascular Research Center

$20,000

Nucleoside therapy for telomere diseases

Agarwal Suneet

Boston Children's Hospital

$63,000.00

Targeting the endocannabinoid system to treat epilepsy in Niemann Pick disease type C

Lola Ledesma

Centro Biologia Molecular Severo Ochoa

$40,140.00

Antisense Oligonucleotide as Substrate Reduction Therapy for Mucopolysaccharidoses type III

Manor Yehoshua

Sheba Medical Center

$57,645.00

Social Outcomes in Adults with RASopathies: The SOAR Study

Jonathan Payne

Murdoch Children's Research Institute

$60,755.00

CLA Chatbot: Developing a Scalable Artificial Intelligence-Powered Communication Tool for Families Affected by Complex Lymphatic Anomalies

Bryan Sisk

Washington University

$60,679.00

Neuromuscular Activation of Muscle in Children with the ZC4H2 Mutation

Richard Lieber

Shirley Ryan AbilityLab

$61,815.00

The mitochondrial-related defects in WDR45-defective cells and how to reverse them

Mario MautheUniversity

Medical Center Groningen (UMCG)

$60,000.00

Advancing gene therapy for BPAN

Manju Kurian

UCL

$60,000.00

Exploring CDKL5 Impact on Extracellular Vesicle-Mediated Cell-to-Cell Communication: Uncovering Hidden Pathways and Innovative Therapeutic Avenues

Maurizio Giustetto

University of Torino

$60,960.00

Development of the novel treatment of idiopathic multicentric Castleman Disease using patientderived cell transplantation in an immunodeficient mouse

Takuya Harada

National Hospital Organization Kyushu Medical Center

$63,270.00

Immunotherapy and improved diagnosis and prognosis of the small vessel disease CADASIL

Helena Karlström

Karolinska Institutet

$109,856.00

Channel scaffolding and its contribution to SCN2A disorders

Paul Jenkins

University of Michigan Medical School

$61,280.00

Systematic dissection of STXBP1 3’ UTR regulation to facilitate therapeutic development

Xuebing Wu

Columbia University

$75,460.00

Integrative omics: A novel approach to unravelling the complexity of STXBP1 encephalopathies

Wendy Gold

The University of Sydney

$75,460.00

Developing peptide-conjugated antisense oligonucleotide therapy for COL6-related congenital muscular dystrophy

Haiyan Zhou

University College London

$70,133.00

ADAR mediated RNA editing for treatment of collagen VI related muscular dystrophy

Russell Butterfield

University of Utah

$70,133.00

pH-dependent mechanisms of disease caused by TBC1D24 mutations

Dennis Brown

Massachusetts General Hospital

$60,000.00

Linking SETBP1-HD EEG Biomarkers to Clinical Profiles

Caitlin Hudac

University of South Carolina

$88,740.00

Clinical trial readiness through longitudinal disease reconstruction in TBC1D24-related disorders

Jillian McKee

University of Pennsylvania/ Children's Hospital of Philadelphia

$26,962.00

Congenital hyperinsulinism models for novel drug discovery

Michael Kalwat

Indiana Biosciences Research Institute

$70,200.00

Targeting immunosuppression in LAM

Yan Tang

Brigham and Women's Hospital, Harvard Medical School

$71,051.00

Rescue of defective lipid handling in Cohen syndrome

Jens Luders

Institute for Research in Biomedicine (IRB Barcelona), Spain

$83,282.00

Deep Tissue and Cellular Phenotyping of APBD: A Bench to Bedside Approach

Priya Kishnani

Duke University Medical Center

$50,000.00

Combinations of small molecule as potential therapeutic agents for APBD

Or Kakhlon

Research Fund of the Hadassah Medical Organization

$50,000.00

Testing the specificity and efficacy of compounds that inhibit cAMP signaling, for the development of potential therapeutics for FD/MAS

Fernando Fierro

University of California Davis

$80,642.00

Spatial transcriptomics to elucidate the mechanism of anti-RANKL inhibition of fibrous dysplasia bone lesions

Julia Charles

Brigham and Women's Hospital

$40,321.00

Probing Central and Peripheral Mechanisms of Pain and Dysfunction in Fibrous Dysplasia/McCune-Albright

Jaymin Upadhyay

Boston Children's Hospital

$40,321.00

 
 

For complete grant list click here